Dr. Reddy's Board Approves Audited FY26 Results, Recommends ₹8 Dividend, Appoints New Directors
Dr. Reddy's Board approved audited FY26 results, with Q4 revenues at ₹75,162 million and FY26 revenues at ₹335,933 million. A final dividend of ₹8 per share was recommended. The company approved the AGM on July 23, 2026, and re-appointed Dr. K P Krishnan and appointed Mr. Srikanth Velamakanni as Independent Directors.
The announcement contains significant corporate actions including the approval of financial results, dividend recommendation, appointment of new directors, and auditor appointments, which are material information for investors.
The announcement includes the approval of financial results and dividend recommendation, which are routine corporate actions. While the financial results show a decline in Q4, the overall tone is neutral as it reports factual outcomes of the board meeting.
Dr. Reddy's Laboratories Limited announced the outcome of its Board Meeting held on May 12, 2026. The Board approved the Audited Financial Results for the quarter and financial year ended March 31, 2026, including consolidated and standalone statements prepared under IFRS and Ind AS, respectively. A final dividend of ₹8 per equity share for FY2025-26 was recommended, subject to shareholder approval at the ensuing Annual General Meeting (AGM). The record date for this dividend has been fixed as July 10, 2026. The 42nd AGM is scheduled for Thursday, July 23, 2026.
Key appointments and re-appointments were also approved. Dr. K P Krishnan was re-appointed as an Independent Director for a second term from January 7, 2027, to January 6, 2032. Mr. Srikanth Velamakanni was appointed as an Additional Director, categorized as an Independent Director, for a term of five years from July 1, 2026, to June 30, 2031. M/s Deloitte Haskins & Sells, LLP, has been appointed as the Statutory Auditors for five years, commencing from the conclusion of the 42nd AGM. M/s Sagar & Associates have been re-appointed as Cost Auditors for FY2026-27. Additionally, Mr. Sandeep Khandelwal was elevated to Senior Management Personnel and inducted as a member of the Management Council, effective May 12, 2026.
The financial results for the quarter ended March 31, 2026, showed revenues of ₹75,162 million and a profit after tax attributable to equity holders of ₹2,201 million. For the full financial year ended March 31, 2026, revenues were ₹335,933 million and profit after tax was ₹42,850 million. The company highlighted the impact of a Shelf Stock Adjustment related to lenalidomide, impairment of CAR-T assets, and provisions related to VAT liability on its Q4FY26 performance.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.